Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Barbara Yawn

Rochester, MN Medical Doctor

CMS profile 1381089

826 19Th St Ne, Rochester, MN 55906

Open in the dashboard

General payments

$255,076

170 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$157,364 paid to institutions, not to them · program year 2021

Through program year 2025, Barbara Yawn of Rochester, MN is reported in the CMS Open Payments database as having received $255,076 across 170 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $157,364 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $750 1
2024 General $42,306 17
2023 General $43,883 36
2022 General $26,382 13
2021 General $27,518 15
2020 General $56,695 24
2019 General $57,542 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barbara Yawn
  • Minnesota median
  • Middle half of Minnesota
  • National median

In program year 2025, general payments to Barbara Yawn were reported at $750. Among 10,790 Minnesota profiles paid that year, the median was $105 and the middle half received between $34 and $362.

Show as a table
Year Barbara Yawn Minnesota median Middle half National median
2019 $57,542 $112 $30–$609 $163
2020 $56,695 $84 $23–$447 $114
2021 $27,518 $87 $25–$376 $132
2022 $26,382 $98 $30–$364 $149
2023 $43,883 $112 $34–$406 $160
2024 $42,306 $108 $34–$386 $164
2025 $750 $105 $34–$362 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $154,040 91 payments
  2. AstraZeneca Pharmaceuticals LP $51,865 57 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $34,792 16 payments
  4. Teva Pharmaceuticals USA, Inc. $7,000 2 payments
  5. Sunovion Pharmaceuticals Inc. $5,558 1 payment
  6. Boehringer Ingelheim International GmbH $1,200 1 payment
  7. AstraZeneca UK Limited $622 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $194,617 74 payments
  2. Travel and Lodging $41,924 51 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,355 7 payments
  4. Food and Beverage $2,180 38 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $22,130 14 payments
  2. STIOLTO RESPIMAT Respiratory $17,736 8 payments
  3. AIRSUPRA $14,195 19 payments
  4. BREZTRI $14,125 11 payments
  5. SHINGRIX $12,666 17 payments
  6. FASENRA Respiratory $10,550 6 payments
  7. FASENRA Respiratory $9,554 14 payments
  8. STIOLTO $9,225 2 payments
  9. STIOLTO RESPIMAT Respiratory $4,652 3 payments
  10. NUCALA $3,488 2 payments
  11. Other $3,122 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

170 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record